Tango Therapeutics Stock Alpha and Beta Analysis
| TNGX Stock | USD 3.10 0.16 5.44% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tango Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tango Therapeutics over a specified time horizon. Remember, high Tango Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tango Therapeutics' market risk premium analysis include:
Beta (2.09) | Alpha (1.20) | Risk 6.84 | Sharpe Ratio (0.16) | Expected Return (1.10) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Tango |
Tango Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tango Therapeutics market risk premium is the additional return an investor will receive from holding Tango Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tango Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tango Therapeutics' performance over market.| α | -1.2 | β | -2.09 |
Tango Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Tango Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Tango Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Tango Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Tango Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tango Therapeutics shares will generate the highest return on investment. By understating and applying Tango Therapeutics stock market price indicators, traders can identify Tango Therapeutics position entry and exit signals to maximize returns.
Tango Therapeutics Return and Market Media
The median price of Tango Therapeutics for the period between Tue, Sep 24, 2024 and Mon, Dec 23, 2024 is 5.16 with a coefficient of variation of 34.99. The daily time series for the period is distributed with a sample standard deviation of 1.8, arithmetic mean of 5.16, and mean deviation of 1.67. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 10/10/2024 |
2 | Disposition of 625000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 7.05 subject to Rule 16b-3 | 10/21/2024 |
3 | Disposition of 250000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.78 subject to Rule 16b-3 | 10/22/2024 |
4 | Disposition of 633000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.87 subject to Rule 16b-3 | 10/25/2024 |
5 | Acquisition by Davis Aaron I. of 65000 shares of Tango Therapeutics at 10.93 subject to Rule 16b-3 | 11/01/2024 |
6 | Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program | 11/06/2024 |
7 | Disposition of 1143124 shares by Ecor1 Capital, Llc of Tango Therapeutics at 2.9171 subject to Rule 16b-3 | 11/07/2024 |
8 | Tango Therapeutics, Inc. Insider Boxer Capital Management, Llc Sells 3,080,000 Shares of Stock | 11/08/2024 |
9 | Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.62 subject to Rule 16b-3 | 11/14/2024 |
10 | Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.78 subject to Rule 16b-3 | 11/18/2024 |
11 | Tango Therapeutics, Inc. Director Purchases 37,800.00 in Stock | 11/19/2024 |
12 | Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference | 11/27/2024 |
13 | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 12/03/2024 |
14 | Tango Therapeutics, Inc. Receives Consensus Recommendation of Buy from Analysts - MarketBeat | 12/09/2024 |
About Tango Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tango or other stocks. Alpha measures the amount that position in Tango Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 19.71 | 29.36 | 33.77 | 52.95 | PTB Ratio | 1.97 | 2.55 | 3.7 | 6.45 |
Tango Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Tango Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tango Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tango Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tango Therapeutics. Please utilize our Beneish M Score to check the likelihood of Tango Therapeutics' management manipulating its earnings.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Tango Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.